{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,11]],"date-time":"2026-06-11T02:57:44Z","timestamp":1781146664836,"version":"3.54.1"},"reference-count":40,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"3","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,6]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>Neonatal and infantile epilepsies represent a diverse group of disorders with significant neurodevelopmental impact, necessitating early diagnosis, and tailored treatment. Recent advancements in genetic research, phenotyping, and therapeutic development have reshaped the understanding and management of these conditions, making this review both timely and relevant.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Next-generation sequencing has emerged as a cornerstone for diagnosing neonatal and infantile epilepsies, offering high diagnostic yields and enabling identification of etiology-specific phenotypes. Precision therapies, including sodium channel blockers, ganaxolone, and mammalian target of rapamycin (mTOR) inhibitors, target specific molecular mechanisms. Early initiation of treatment in conditions with a high risk of progressing to epilepsy, like vigabatrin in tuberous sclerosis complex, lower the incidence of infantile spasms and improve developmental outcomes. Drug repurposing has also provided effective options, such as fenfluramine in Dravet syndrome, with promising outcomes. Gene-based therapies, including antisense oligonucleotides and gene replacement, represent the new frontier for addressing the root causes of these disorders.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>The integration of genetic and molecular advancements is transforming the management of neonatal and infantile epilepsies, fostering precision-driven care. Continued research and innovation are essential to refine these strategies, optimize patient outcomes, and establish new standards of care.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/mop.0000000000001448","type":"journal-article","created":{"date-parts":[[2025,2,11]],"date-time":"2025-02-11T11:00:56Z","timestamp":1739271656000},"page":"303-308","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["Update on neonatal and infantile onset epilepsies"],"prefix":"10.1097","volume":"37","author":[{"given":"Evelina","family":"Carapancea","sequence":"first","affiliation":[{"name":"Institute of Neuroscience, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tristan T.","family":"Sands","sequence":"additional","affiliation":[{"name":"Division of Child Neurology, Department of Neurology, Columbia University Vagelos College of Physicians and Surgeons, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Roberta","family":"Cilio","sequence":"additional","affiliation":[{"name":"Institute of Neuroscience, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"},{"name":"Division of Pediatric Neurology, Department of Pediatrics, Cliniques Universitaires Saint-Luc, Universit\u00e9 Catholique de Louvain, Brussels, Belgium"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,2,10]]},"reference":[{"key":"R1-20250506","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1002\/jgc4.1646","article-title":"Genetic testing and counseling for the unexplained epilepsies: an evidence-based practice guideline of the National Society of Genetic Counselors","volume":"32","author":"Smith","year":"2023","journal-title":"J Genet Couns"},{"key":"R2-20250506","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1111\/epi.17239","article-title":"ILAE classification and definition of epilepsy syndromes with onset in neonates and infants: Position statement by the ILAE Task Force on Nosology and Definitions","volume":"63","author":"Zuberi","year":"2022","journal-title":"Epilepsia"},{"key":"R3-20250506","doi-asserted-by":"crossref","first-page":"2550","DOI":"10.1111\/epi.17745","article-title":"Treatment of seizures in the neonate: guidelines and consensus-based recommendations\u2014Special report from the ILAE Task Force on Neonatal Seizures","volume":"64","author":"Pressler","year":"2023","journal-title":"Epilepsia"},{"key":"R4-20250506","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1002\/ana.25956","article-title":"Prevention of epilepsy in infants with tuberous sclerosis complex in the EPISTOP trial","volume":"89","author":"Kotulska","year":"2021","journal-title":"Ann Neurol"},{"issue":"(96)","key":"R5-20250506","first-page":"868","article-title":"The development of neonatal neurointensive care","author":"Austin","year":"2019","journal-title":"Pediatr Res"},{"key":"R6-20250506","doi-asserted-by":"crossref","first-page":"3027","DOI":"10.3390\/jcm11113027","article-title":"Nonketotic hyperglycinemia: insight into current therapies","volume":"11","author":"Nowak","year":"2022","journal-title":"J Clin Med"},{"key":"R7-20250506","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1111\/j.1469-8749.2012.04347.x","article-title":"Long-term outcome in pyridoxine-dependent epilepsy","volume":"54","author":"Bok","year":"2012","journal-title":"Dev Med Child Neurol"},{"key":"R8-20250506","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ymgme.2015.05.011","article-title":"Triple therapy with pyridoxine, arginine supplementation and dietary lysine restriction in pyridoxine-dependent epilepsy: neurodevelopmental outcome","volume":"116","author":"Coughlin","year":"2015","journal-title":"Mol Genet Metab"},{"key":"R9-20250506","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.ejpn.2023.07.006","article-title":"A novel approach to seizures in neonates","volume":"46","author":"Carapancea","year":"2023","journal-title":"Eur J Paediatr Neurol"},{"key":"R10-20250506","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1111\/epi.16957","article-title":"Neonatal presentation of genetic epilepsies: early differentiation from acute provoked seizures","volume":"62","author":"Cornet","year":"2021","journal-title":"Epilepsia"},{"key":"R11-20250506","doi-asserted-by":"crossref","first-page":"e1234","DOI":"10.1212\/WNL.0000000000206755","article-title":"Clinical and neurophysiologic phenotypes in neonates with BRAT1 encephalopathy","volume":"100","author":"Carapancea","year":"2023","journal-title":"Neurology"},{"key":"R12-20250506","doi-asserted-by":"crossref","first-page":"e603","DOI":"10.1212\/WNL.0000000000201492","article-title":"Neurodevelopmental and epilepsy phenotypes in individuals with missense variants in the voltage-sensing and pore domains of KCNH5","volume":"100","author":"Happ","year":"2023","journal-title":"Neurology"},{"key":"R13-20250506","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1212\/WNL.0000000000200738","article-title":"Teaching video neuroimage: neonate with complex movement disorder and seizures","volume":"99","author":"Grande","year":"2022","journal-title":"Neurology"},{"key":"R14-20250506","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamaneurol.2021.1437","article-title":"Safety of early discontinuation of antiseizure medication after acute symptomatic neonatal seizures","volume":"78","author":"Glass","year":"2021","journal-title":"JAMA Neurol"},{"key":"R15-20250506","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/j.1749-6632.2003.tb07517.x","article-title":"Antiepileptic drugs and apoptosis in the developing brain","volume":"993","author":"Bittigau","year":"2003","journal-title":"Ann N Y Acad Sci"},{"key":"R16-20250506","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1177\/000992289903800702","article-title":"Late cognitive effects of early treatment with phenobarbital","volume":"38","author":"Sulzbacher","year":"1999","journal-title":"Clin Pediatr (Phila)"},{"key":"R17-20250506","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00018-005-5348-0","article-title":"Antiepileptic drugs and the developing brain","volume":"63","author":"Kaindl","year":"2006","journal-title":"Cell Mol Life Sci"},{"issue":"(Suppl 5)","key":"R18-20250506","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1528-1167.2007.01285.x","article-title":"Neurodevelopmental impact of antiepileptic drugs and seizures in the immature brain","volume":"48","author":"Kim","year":"2007","journal-title":"Epilepsia"},{"key":"R19-20250506","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.jpeds.2021.09.058","article-title":"Neonatal seizure management: is the timing of treatment critical?","volume":"243","author":"Pavel","year":"2022","journal-title":"J Pediatr"},{"key":"R20-20250506","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1016\/S0140-6736(16)31419-2","article-title":"Adjunctive everolimus therapy for treatment-resistant focal-onset seizures associated with tuberous sclerosis (EXIST-3): a phase 3, randomised, double-blind, placebo-controlled study","volume":"388","author":"French","year":"2016","journal-title":"Lancet"},{"key":"R21-20250506","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1007\/s40120-023-00476-7","article-title":"Effect of mTOR inhibitors in epilepsy treatment in children with tuberous sclerosis complex under 2 years of age","volume":"12","author":"\u015amia\u0142ek","year":"2023","journal-title":"Neurol Ther"},{"key":"R22-20250506","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1111\/epi.17444","article-title":"SCN1A gain-of-function mutation causing an early onset epileptic encephalopathy","volume":"64","author":"Clatot","year":"2023","journal-title":"Epilepsia"},{"issue":"(S3)","key":"R23-20250506","first-page":"59","article-title":"Phenotypic spectrum and genetics of SCN 2A-related disorders, treatment options, and outcomes in epilepsy and beyond","volume":"60","author":"Wolff","year":"2019","journal-title":"Epilepsia"},{"key":"R24-20250506","doi-asserted-by":"crossref","first-page":"e1112","DOI":"10.1212\/WNL.0000000000006199","article-title":"The phenotype of SCN8A developmental and epileptic encephalopathy","volume":"91","author":"Gardella","year":"2018","journal-title":"Neurology"},{"key":"R25-20250506","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.seizure.2021.07.013","article-title":"PRRT2 variants and effectiveness of various antiepileptic drugs in self-limited familial infantile epilepsy","volume":"91","author":"Zhao","year":"2021","journal-title":"Seizure"},{"key":"R26-20250506","doi-asserted-by":"crossref","first-page":"2019","DOI":"10.1111\/epi.13596","article-title":"Rapid and safe response to low-dose carbamazepine in neonatal epilepsy","volume":"57","author":"Sands","year":"2016","journal-title":"Epilepsia"},{"key":"R27-20250506","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1111\/epi.12984","article-title":"Early and effective treatment of KCNQ2 encephalopathy","volume":"56","author":"Pisano","year":"2015","journal-title":"Epilepsia"},{"key":"R28-20250506","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1080\/14737175.2017.1253476","article-title":"Precision medicine in genetic epilepsies: break of dawn?","volume":"17","author":"Reif","year":"2017","journal-title":"Expert Rev Neurother"},{"key":"R29-20250506","doi-asserted-by":"crossref","first-page":"e143","DOI":"10.1111\/epi.17627","article-title":"Ezogabine impacts seizures and development in patients with KCNQ2 developmental and epileptic encephalopathy","volume":"64","author":"Knight","year":"2023","journal-title":"Epilepsia"},{"key":"R30-20250506","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.1111\/epi.16394","article-title":"Personalized medicine: vinpocetine to reverse effects of GABRB3 mutation","volume":"60","author":"Billakota","year":"2019","journal-title":"Epilepsia"},{"key":"R31-20250506","doi-asserted-by":"crossref","first-page":"eaaz4957","DOI":"10.1126\/scitranslmed.aaz4957","article-title":"4-Aminopyridine is a promising treatment option for patients with gain-of-function KCNA2-encephalopathy","volume":"13","author":"Hedrich","year":"2021","journal-title":"Sci Transl Med"},{"key":"R32-20250506","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"key":"R33-20250506","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with Dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2020","journal-title":"JAMA Neurol"},{"key":"R35-20250506","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/S1474-4422(22)00077-1","article-title":"Safety and efficacy of ganaxolone in patients with CDKL5 deficiency disorder: results from the double-blind phase of a randomised, placebo-controlled, phase 3 trial","volume":"21","author":"Knight","year":"2022","journal-title":"Lancet Neurol"},{"key":"R36-20250506","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1111\/epi.14551","article-title":"Lack of response to quinidine in KCNT1-related neonatal epilepsy","volume":"59","author":"Numis","year":"2018","journal-title":"Epilepsia"},{"key":"R37-20250506","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1111\/ene.15975","article-title":"Everolimus precision therapy for the GATOR1-related epilepsies: a case series","volume":"30","author":"Moloney","year":"2023","journal-title":"Eur J Neurol"},{"key":"R38-20250506","doi-asserted-by":"crossref","first-page":"e70050","DOI":"10.1111\/cns.70050","article-title":"Antisense oligonucleotides as a precision therapy for developmental and epileptic encephalopathies","volume":"30","author":"Quil\u00f3n","year":"2024","journal-title":"CNS Neurosci Ther"},{"key":"R39-20250506","doi-asserted-by":"crossref","first-page":"147743","DOI":"10.1016\/j.brainres.2021.147743","article-title":"Targeted Augmentation of Nuclear Gene Output (TANGO) of Scn1a rescues parvalbumin interneuron excitability and reduces seizures in a mouse model of Dravet Syndrome","volume":"1775","author":"Wengert","year":"2022","journal-title":"Brain Res"},{"key":"R40-20250506","doi-asserted-by":"crossref","first-page":"3331","DOI":"10.1016\/j.ymthe.2024.07.012","article-title":"Preclinical studies of gene replacement therapy for CDKL5 deficiency disorder","volume":"32","author":"Voronin","year":"2024","journal-title":"Mol Ther"},{"key":"R41-20250506","doi-asserted-by":"crossref","first-page":"104632","DOI":"10.1016\/j.jbc.2023.104632","article-title":"The intramembrane COOH-terminal domain of PRRT2 regulates voltage-dependent Na+ channels","volume":"299","author":"Franchi","year":"2023","journal-title":"J Biol Chem"}],"container-title":["Current Opinion in Pediatrics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001448","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,6]],"date-time":"2025-05-06T16:00:18Z","timestamp":1746547218000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MOP.0000000000001448"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,10]]},"references-count":40,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/mop.0000000000001448","relation":{},"ISSN":["1531-698X"],"issn-type":[{"value":"1531-698X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,10]]}}}